Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seres Therapeutics Inc (NQ: MCRB )

0.6777 -0.1723 (-20.27%)
Streaming Delayed Price Updated: 12:01 PM EDT, Jun 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Seres Therapeutics Inc

< Previous 1 2 3 4 Next >
Seres Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2021
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present at JMP Securities Life Sciences Conference
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Host Virtual Investor Event on June 21, 2021
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present at Upcoming Virtual Investor Conferences
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present Clinical Research on the Microbiome’s Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Host First Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2021
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present at Jefferies Microbiome-Based Therapeutics Summit
From Seres Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.